Call Us: 1.800.873.5297

By

Actos® Lawsuit Update: Philadelphia Jury Returns $2.3 Million Verdict In Favor of the Plaintiff

Bloomberg reports that a Philadelphia jury has returned a $2.3 million verdict in favor of the plaintiff after finding that the diabetes drug Actos® had been a significant cause of the plaintiff’s bladder cancer. The case is Kristufek v. Takeda Pharmaceuticals America Inc., Philadelphia Court of Common Pleas, Case ID 120702275. The jury also found that […]

By

Research Reveals Big Pharmaceutical Companies Spending More on Sales and Marketing than Research and Development

According to the Washington Post, a study conducted by the healthcare research firm GlobalData revealed that nine out of ten big pharmaceutical companies are spending more on sales and marketing than research and development (R&D). Johnson & Johnson, the biggest spender, expended roughly $17.5 billion dollars on sales and marketing in 2013, compared with $8.2 billion […]

By

AstraZeneca Pays $7.9 Million for Alleged Violations of Anti-Kickback Laws

The Wall Street Journal reports that the drug manufacturer, AstraZeneca, will pay $7.9 million to the federal government over allegations that the manufacturer violated anti-kickback laws and attempted to defraud the federal, state, and local U.S. governments. The drugmaker is accused of paying kickbacks to a large Pharmacy Benefits Manager in exchange for a guarantee that […]

By

Xarelto® Lawsuit Update: Roger C. Denton of Schlichter, Bogard & Denton, LLP Appointed to Plaintiffs’ Steering Committee

On February 9, 2015 the Honorable Eldon Fallon, sitting in the U.S. District Court for the Eastern District of Louisiana, appointed Roger C. Denton of Schlichter, Bogard & Denton, LLP to the Plaintiffs’ Steering Committee (PSC) in the national Xarelto® Multidistrict Litigation (In Re: Xarelto (Rivaroxaban) Products Liability Litigation, Case No. 2:14-md-02592, MDL 2592, Pretrial […]

By

Federal Judge Orders Permanent Injunction against Certain Medical Device Manufacturers

The FDA reports  that a Federal Judge sitting in the U.S. District Court of New Hampshire entered a consent decree of permanent injunction against four medical device manufacturing companies and two company officers. Between 2009 and 2013, the U.S. Food and Drug Administration (FDA) conducted ten inspections across the manufacturing sites. Inspections revealed multiple and […]

By

Alere INRatio® Test Strips, Monitor System Recalled

If you have been taking a blood-thinning drug (such as warfarin/Coumadin) or have been receiving heparin injections, you should be aware of an urgent recall of INRatio® PT/INR test strips and monitors. These products are used to test a patient’s INR (international normalized ratio) when taking warfarin and other anticoagulation medications. The goal with warfarin […]

By

Johnson & Johnson Faces Trial in Risperdal® Breast-Development Case

Johnson & Johnson (J&J) will face trial to defend itself against claims that its antipsychotic drug, Risperdal®, causes gynecomastia, a condition that causes young boys and males to grow breasts. The lawsuit, brought in the Philadelphia Court of Common Pleas, involves a boy who ingested Risperdal®  at the age of 8 and subsequently suffered from […]

By

Pfizer Agrees to $400 Million Settlement in Class-Action Securities Lawsuit Involving Investors

The Wall Street Journal reports that Pfizer has agreed to pay $400 million to settle a class-action securities lawsuit alleging that the company illegally marketed several medications causing its investors to lose money, according to a filing with the United States Securities and Exchange Commission (SEC). The securities lawsuit alleged that Pfizer marketed several drugs […]

By

Effexor Plaintiffs Seek to Drop 40% of Lawsuits from MDL

Law360 reports that the plaintiffs in a multidistrict litigation involving Effexor, a depression and anxiety medication manufactured by Wyeth Pharmaceuticals Inc., have sought to dismiss 26 lawsuits targeting the Pfizer unit over the drug’s alleged risk of birth defects. The multidistrict litigation is In re: Effexor (Venlafaxine Hydrochloride) Products Liability Litigation, MDL 2458. Judge Cynthia […]

By

According to Expert in Philadelphia State Court Case, Actos Largest Bladder Cancer Risk for Plaintiff

Law 360 reports that setting aside a history of smoking and other risk factors, an expert witness told a jury in Philadelphia that the most significant contributing factor for the retired western Pennsylvania teacher, who was diagnosed with bladder cancer in 2008, was his long-term Actos use. University of Colorado oncologist and bladder cancer specialist […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.